Table 1.
Comparison of salient patients’ characteristicsa between the Ranibizumab and Aflibercept group at baseline, after completing the loading dose phase and after 1 year
| Ranibizumab (16 eyes) | Aflibercept (11 eyes) | Difference | Confidence interval | p-value | |
|---|---|---|---|---|---|
| Baseline | |||||
| Age (mean ± SD) [years] | 77.6 ± 9.20 | 75 ± 6.74 | 2.63 | −4.08 to 9.33 | 0.428 |
| Female gender n (%) | 11 (68.8 %) | 8 (72.7 %) | 0.586 | ||
| Right eye n (%) | 7 (43.8 %) | 6 (54.5 %) | 0.436 | ||
| Cataract n (%) | 9 (56.3 %) | 9 (81.8 %) | 0.167 | ||
| Serous PED n (%) | 3 (18.8 %) | 2 (18.2 %) | 0.684 | ||
| Classic CNV n (%) | 7 (43.8 %) | 3 (27.3 %) | 0.324 | ||
| Loading phase | |||||
| Letters before treatment (mean ± SD) | 52.25 ± 23.38 | 62.55 ± 22.20 | −10.30 | −28.78 to 8.19 | 0.262 |
| CFT before treatment (mean ± SD) [μm] | 492.80 ± 165.60 | 352.50 ± 168.51 | 140.36 | 5.83 to 274.88 | 0.042 |
| Letters after loading dose (mean ± SD) | 66.06 ± 10.49 | 68.91 ± 8.51 | −2.85 | −10.71 to 5.01 | 0.463 |
| CFT after loading dose (mean ± SD) [μm] | 323.75 ± 93.00 | 267.73 ± 65.18 | 56.02 | −10.93 to 122.98 | 0.097 |
| 1 year | |||||
| Letters after 1 year (mean ± SD) | 67.25 ± 12.69 | 68.18 ± 13.06 | −0.93 | −11.29 to 9.43 | 0.856 |
| CFT after 1 year (mean ± SD) [μm] | 337.31 ± 110.14 | 274.00 ± 77.76 | 63.31 | −16.13 to 142.75 | 0.113 |
| Number of injections/year | 8.28 ± 2.07 | 8.49 ± 1.97 | −0.22 | −1.85 to 1.42 | 0.787 |
aDescriptives were based on eyes